Key outcomes and addressing remaining challenges-Perspectives from a final evaluation of the China GAVI project

Vaccine

Volumn 31, Issue S9, 2013, Pages

  Yang, Weizhong ^a   Liang, Xiaofeng ^a   Cui, Fuqiang ^a   Li, Li ^a   Hadler, Stephen C ^b   Hutin, Yvan J ^c   Kane, Mark ^d   Wang, Yu ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c ECDC (European Center for Diseases Prevention and Control)   (Sweden)

^d Mercer Island   (United States)

Author keywords

Challenges; GAVI; Outcomes; Project

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE PERSONNEL; HEPATITIS B; HIGH RISK PATIENT; HUMAN; IMMUNIZATION; INFECTION CONTROL; PERINATAL INFECTION; PRIORITY JOURNAL; SYRINGE; VACCINATION;

CHALLENGES; GAVI; OUTCOMES; PROJECT;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHINA; COMMUNICABLE DISEASE CONTROL; CROSS-SECTIONAL STUDIES; HEALTH SERVICES RESEARCH; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MIDDLE AGED; PREVALENCE; YOUNG ADULT;

EID: 84892375640     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.09.060     Document Type: Article

References (30)

1. Liang F., Cui F., Hadler S., Wang X., et al. Origins, design and implementation of the China GAVI project. Vaccine. 2013, 31:J8-J14.
2. WHO Tool for the assessment of injection safety. WHO/V&B/01.30 2001.
3. Cui F., Liang X., Gong X., et al. Preventing hepatitis B though universal vaccination: reduction of inequities through the China GAVI Project. Vaccine. 2013, 31:J29-J35.
4. Wu Z., Cui F., Chen Y., et al. Evaluation of immunization injection safety in China, 2010: achievements, future sustainability. Vaccine. 2013, 31:J43-J48.
5. Liang X., Bi S., Yang W., et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009, 27(47):6550-6557.
6. Xia G.L., Liu C.B., Cao H.L., et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. Int Hepatol Commun 1996, 5:62-73.
7. Qu Z. An epidemiological study on the distribution of HBsAg and anti-HBs in China. Chin J Microbiol Immunol 1986, (Suppl.):19-47.
8. WHO Hepatitis B vaccine, WHO position paper. Wkly Epidemiol Rec 2009, 84:405-420.
9. WPRO Progress towards meeting the 2012 hepatitis B control milestone: WHO Western Pacific Region, 2011. Wkly Epidemiol Rec 2011, 86(19):180-188.
10. Wu W.D., Liu D.W., Wu B.B. Study on the surveillance of adverse events following immunization in China: 2007-2008. Chin J Vacc Immun 2009, 15(6):481-490.
11. Liu D., Guo B., Cao L., et al. Study on the surveillance of adverse events following immunization in China: 2005-2006. Chin J Vacc Immun 2007, 13(6):505-513.
12. Wang F., Cui F., Liu D., et al. Analysis on the adverse events following immunization of 10 infants death after hepatitis B vacciantion. Chin J Vacc Immun 2009, 15(1):52-57.
13. UNICEF Building trust and responding to adverse events following immunization in south Asia 2005.
14. WHO Hepatitis B vaccines: WHO position paper-recommendations. Vaccine 2010, 28(3):589-590.
15. Progress towards meeting the 2012 hepatitis B control milestone: WHO Western Pacific Region, 2011. Wkly Epidemiol Rec 2011, 86(19):180-188.
16. Lee C., Gong Y., Brok J., Boxall E.H., Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev (Online) 2006, 2. CD004790.
17. Cui F.Q., Wang X.J., Cao L., et al. Progress in hepatitis B prevention through universal infant immunization-China: 1997-2006. MMWR 2007, 56(18):441-445.
18. WHO Worker's health:global plan of action. The sixtieth world health assembly 2007, WHA60.26.
19. WHO Viral hepatitis, A63/15. Sixty-third world health assembly 2010.
20. Ding S., Li Z. The analysis on Chinese new health reforming system and it'ssustainability 2008, Xiamen Medical University Express, Xiamen.
21. Ding D., Kilgore P.E., Clemens J.D., Wei L., Zhi-Yi X. Cost-effectiveness of routine immunization to control Japanese encephalitis in Shanghai: China. Bull World Health Organ 2003, 81(5):334-342.
22. Yin Z., Wang H., Yang J., et al. Japanese encephalitis disease burden and clinical features of Japanese encephalitis in four cities in the People's Republic of China. Am J Trop Med Hyg 2010, 83(4):766-773.
23. Wu G.Y., Gong Y.L., Yu S.L., Shao R.T., Qin H.J. Study on the cost-effectiveness: benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai. Zhonghua Liu Xing Bing Xue Za Zhi 2004, 25(6):474-478.
24. Pruss-Ustun A., Rapiti E., Hutin Y. Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med 2005, 48(6):482-490.
25. Cui F., Gong X., Chen Y., et al. Evaluation on impact of hepatitis B vaccine integrated into routine immunization in Ministry of Health/Global Alliance for Vaccine and Immunization GAVI cooperation project areas, P.R. China. Chin J Vacc Immun 2009, 15(4):289-293.
26. Hutton D.W., So S.K., Brandeau M.L. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 2010, 51(2):405-414.
27. Talaat M., Kandeel A., El-Shoubary W., et al. Occupational exposure to needlestick injuries and hepatitis B vaccination coverage among health care workers in Egypt. Am J Infect Control 2003, 31(8):469-474.
28. Mayo Ferreiro F., Smyth Chamosa E., Figueiras A. Vaccination for the hepatitis B virus in primary care health staff: prevalence, affecting factors and need. Aten Primaria 1998, 22(1):13-20.
29. Sangfelt P., Uhnoo I., Reichard O., Weiland O. A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical setting. Scand J Gastroenterol 2008, 43(4):465-472.
30. Lanphear B.P. Hepatitis B immunoprophylaxis: developing a cost-effective program in the hospital setting. Infect Control Hosp Epidemiol 1990, 11(1):47-50.